Genmab Combination Cuts Death Risk 50% in Phase 3 Cancer Trial

Phase 3 LiGeR-HN1 trial of Petosemtamab in combination with pembrolizumab versus pembrolizumab alone

Genmab A/S (NASDAQ:GMAB) today announced positive topline results from the global Phase 3 LiGeR-HN1 trial (NCT06525220) evaluating petosemtamab, an investigational IgG1-bispecific antibody targeting the epidermal growth factor receptor (EGFR) and the leucine-rich repeat containing G-protein-coupled…

Company Announcement COPENHAGEN, Denmark; October 28, 2026 Phase 3 LiGeR-HN1 trial of Petosemtamab i

Genmab said the Phase 3 LiGeR-HN1 trial of petosemtamab plus pembrolizumab met dual primary endpoints in PD-L1+ 1L HNSCC, cutting death risk by 50% vs pembrolizumab and improving ORR; safety was consistent. The company plans to engage regulators and present full data.Material DetailsContext by AI A…

Petosemtamab de Genmab combinado con pembrolizumab reduce un 50% el riesgo de muerte en ensayo de fa

GENMAB - PHASE 3 LIGER-HN1 TRIAL MEETS BOTH PRIMARY ENDPOINTS, REDUCES RISK OF DEATH BY 50%

GENMAB SHARES UP 10% AFTER RESULTS FROM PHASE 3 LIGER-HN1 TRIAL OF PETOSEMTAMA

Genmab A/S OMXCOP:GMAB